



Figure S7. Galunisertib and anti-PD-1 dual treatment promotes GranzymeB production in tumor infiltrating CTLs

(A) Pdx1-Cre x LSL-KRAS^{G12D} x TP53^{R172H} (KPC) mice were treated with Galunisertib, and/or anti-PD-1 as described and tissues stained for both CD3 and GranzymeB. **(B)** CD3 and GranzymeB dual-positive cells were quantified per high power field and averages displayed ± S.E.M. (*p < 0.05, N≤3/group).